Platelet function recovery following exposure to triple anti-platelet inhibitors using an in vitro transfusion model

Thrombosis Research

Volumn 136, Issue 6, 2015, Pages 1216-1223

  Bhal, Vinay ^a   Herr, Michael J ^a   Dixon, Mason ^a   Akins, Steve ^b   Hord, Ed ^a   White, Melanie M ^a   Seiffert, Dietmar ^c   Kotha, Jayaprakash ^a   Jennings, Lisa K ^a,d  

^a CirQuest Labs LLC   (United States)

^b Sutherland Cardiology Clinic   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Aspirin; ; Clopidogrel; ; Platelet aggregation; ; Platelet transfusion; Vorapaxar;

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CLOPIDOGREL; PADGEM PROTEIN; PROTEINASE ACTIVATED RECEPTOR 4; THROMBIN RECEPTOR ACTIVATING PEPTIDE 6; VORAPAXAR; ANTITHROMBOCYTIC AGENT; APOPTOSIS REGULATORY PROTEIN; LACTONE; P2RY12 PROTEIN, HUMAN; PEPTIDE FRAGMENT; PROSTATE APOPTOSIS RESPONSE-4 PROTEIN; PROTEINASE ACTIVATED RECEPTOR; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; PYRIDINE DERIVATIVE; THROMBIN RECEPTOR PEPTIDE (42-47); TICLOPIDINE;

ANTICOAGULANT THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HEMATOLOGICAL PROCEDURE; HUMAN; IN VITRO STUDY; LIGHT TRANSMISSION AGGREGOMETRY; PLATELET REACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTE POOR PLASMA; THROMBOCYTE RICH PLASMA; THROMBOCYTE TRANSFUSION; TREATMENT DURATION; TRIPLE ANTIPLATELET THERAPY; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLEEDING; BLOOD CLOTTING PARAMETERS; BLOOD TRANSFUSION; CHEMISTRY; DRUG EFFECTS; METABOLISM; PROCEDURES; THROMBOCYTE;

APOPTOSIS REGULATORY PROTEINS; ARACHIDONIC ACID; ASPIRIN; BLOOD PLATELETS; BLOOD TRANSFUSION; FLOW CYTOMETRY; HEMORRHAGE; HUMANS; LACTONES; P-SELECTIN; PEPTIDE FRAGMENTS; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PLATELET TRANSFUSION; PURINERGIC P2Y RECEPTOR ANTAGONISTS; PYRIDINES; RECEPTORS, PROTEINASE-ACTIVATED; RECEPTORS, PURINERGIC P2Y12; TICLOPIDINE;

EID: 84949234043     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2015.09.009     Document Type: Article

References (25)

1. L.K. Jennings Role of platelets in atherothrombosis J. Cardiol. 103 2009 4A 10A
2. S. Yusuf, F. Zhao, S.R. Mehta, S. Chrolavicius, G. Tognoni, K.K. Fox, and et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N. Engl. J. Med. 345 2001 494 502
3. L. Wallentin, R.C. Becker, A. Budaj, C.P. Cannon, H. Emanuelsson, C. Held, and et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes N. Engl. J. Med. 361 2009 1045 1057
4. D.A. Morrow, E. Braunwald, M.P. Bonaca, S.F. Ameriso, A.J. Dalby, M.P. Fish, and et al. Vorapaxar in the secondary prevention of atherothrombotic events N. Engl. J. Med. 366 2012 1404 1413
5. P. Tricoci, Z. Huang, C. Held, D.J. Moliterno, P.W. Armstrong, F. Van de Werf, and et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes N. J. Med. 366 2012 20 33
6. M.P. Bonaca, B.M. Scirica, M.A. Creager, J. Olin, H. Bounameaux, M. Dellborg, and et al. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50 Circulation 127 2013 1522 1529 9e1-6
7. M.P. Bonaca, B.M. Scirica, E. Braunwald, S.D. Wiviott, S. Goto, D.W. Nilsen, and et al. New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 degrees P-TIMI 50 trial J. Coll. Cardiol. 64 2014 2318 2326
8. L.K. Jennings, W.C. Wang, C.W. Jackson, C.F. Fox, and A. Bell Hemostasis in Glanzmann's thrombasthenia (GT): GT platelets interfere with the aggregation of normal platelets Am. J. Pediatr. Hematol. Oncol. 13 1991 84 90
9. T. Kosoglou, P. Statkevich, B. Kumar, J. Li, M.F. Dockendorf, and et al. Pharmacokinetics of vorapaxar and its metabolite following oral administration in healthy Chinese and American subjects Int. J. Clin. Pharmacol. Ther. Toxicol. 52 2014 889 899
10. J.E. Wall, M. Buijs-Wilts, J.T. Arnold, W. Wang, M.M. White, L.K. Jennings, and et al. A flow cytometric assay using mepacrine for study of uptake and release of platelet dense granule contents Br. J. Haematol. 89 1995 380 385
11. P. Tricoci, Y. Lokhnygina, Z. Huang, F. Van de Werf, J.H. Cornel, E. Chen, and et al. Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial Am. Heart J. 168 2014 869 877 e1
12. M. Cushman, B.M. Psaty, E. Macy, E.G. Bovill, E.S. Cornell, L.H. Kuller, and et al. Correlates of thrombin markers in an elderly cohort free of clinical cardiovascular disease Arterioscler. Thromb. Vasc. Biol. 16 1996 1163 1169
13. J.I. Borissoff, I.A. Joosen, M.O. Versteylen, H.M. Spronk, H. ten Cate, and L. Hofstra Accelerated in vivo thrombin formation independently predicts the presence and severity of CT angiographic coronary atherosclerosis J. Am. Coll. Cardiol. Img. 5 2012 1201 1210
14. T. Kosoglou, W.K. Kraft, B. Kumar, P. Statkevich, F. Xuan, L. Ma, and et al. Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease Eur. J. Clin. Pharmacol. 68 2012 1049 1056
15. L. Zhou, and A.H. Schmaier Platelet aggregation testing in platelet-rich plasma: description of procedures with the aim to develop standards in the field Am. J. Clin. Pathol. 123 2005 172 183
16. M. Cattaneo Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function Semin. Thromb. Hemost. 35 2009 158 167
17. T.Q. Cai, L.A. Wickham, G. Sitko, M.S. Michener, R. Raubertas, L. Handt, and et al. Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist Eur. J. Pharmacol. 758 2015 107 114
18. K.I. Kalantzi, M.E. Tsoumani, I.A. Goudevenos, and A.D. Tselepis Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives Expert. Rev. Clin. Pharmacol. 5 2012 319 336
19. D.J. Angiolillo The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day Drugs 72 2012 2087 2116
20. C. Li, J. Hirsh, C. Xie, M.A. Johnston, and J.W. Eikelboom Reversal of the anti-platelet effects of aspirin and clopidogrel J. Thromb. Haemost. 10 2012 521 528
21. E.C. Hansson, C. Shams Hakimi, K. Astrom-Olsson, C. Hesse, H. Wallen, M. Dellborg, and et al. Effects of ex vivo platelet supplementation on platelet aggregability in blood samples from patients treated with acetylsalicylic acid, clopidogrel, or ticagrelor Br. J. Anaesth. 112 2014 570 575
22. S. O'Connor, M. Rejane, J. Amour, J. Abtan, M. Kerneis, J. Silvain, and et al. Restoration of platelet function with platelet transfusion in cardiac surgery patients on dual antiplatelet therapy Eur. Heart J. 2013
23. F. Norol, P. Bierling, F. Roudot-Thoraval, F.F. Le Coeur, C. Rieux, A. Lavaux, and et al. Platelet transfusion: a dose-response study Blood 92 1998 1448 1453
24. R.M. Kaufman, B. Djulbegovic, T. Gernsheimer, S. Kleinman, A.T. Tinmouth, K.E. Capocelli, and et al. Platelet transfusion: a clinical practice guideline from the AABB Ann. Intern. Med. 2014
25. W. Korte, M. Cattaneo, P.G. Chassot, S. Eichinger, C. von Heymann, N. Hofmann, and et al. Peri-operative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the working group on perioperative haemostasis of the society on thrombosis and haemostasis research (GTH), the working group on perioperative coagulation of the Austrian society for anesthesiology, resuscitation and intensive care (OGARI) and the working group thrombosis of the European society for cardiology (ESC) Thromb. Haemost. 105 2011 743 749